keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis C virus

keyword
https://www.readbyqxmd.com/read/29779010/low-mir200b-5p-levels-in-minor-salivary-glands-a-novel-molecular-marker-predicting-lymphoma-development-in-patients-with-sj%C3%A3-gren-s-syndrome
#1
Efstathia K Kapsogeorgou, Aristea Papageorgiou, Athanase D Protogerou, Michael Voulgarelis, Athanasios G Tzioufas
OBJECTIVES: Development of non-Hodgkin's lymphoma (NHL) is the major adverse outcome of Sjögren's syndrome (SS) affecting both morbidity and mortality. Preliminary evidence suggested that, although not deregulated compared with sicca controls, miR200b-5p levels are decreased in the minor salivary glands (MSGs) of SS patients with NHL. The aim of the current study was to evaluate the MSG expression of miR200b-5p in SS-associated NHLs and its potential predictive value for the identification of patients with SS susceptible to develop NHL...
May 19, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29779005/hbv-and-hcv-test-uptake-and-correlates-among-men-who-have-sex-with-men-in-china-a-nationwide-cross-sectional-online-survey
#2
Thomas Fitzpatrick, Stephen W Pan, Weiming Tang, Wilson Guo, Joseph D Tucker
OBJECTIVES: Hepatitis B virus (HBV) and hepatitis C virus (HCV) cause substantial morbidity and mortality in low-income and middle-income countries, including China. WHO guidelines recommend men who have sex with men (MSM) receive HBV and HCV screening. The purpose of this study was to determine the proportion of MSM in China who have HBV and HCV tested and identify correlates of test uptake. METHODS: We conducted an online cross-sectional survey of young MSM in China...
May 19, 2018: Sexually Transmitted Infections
https://www.readbyqxmd.com/read/29778602/structure-guided-combinatorial-engineering-facilitates-affinity-and-specificity-optimization-of-anti-cd81-antibodies
#3
Bryce Nelson, Jarrett Adams, Andreas Kuglstatter, Zhijian Li, Seth F Harris, Yang Liu, Sandya Bohini, Han Ma, Klaus Klumpp, Junjun Gao, Sachdev S Sidhu
Hepatitis C viral infection is the major cause of chronic hepatitis that affects as many as 71 million people worldwide. Rather than target the rapidly shifting viruses and their numerous serotypes, four independent antibodies were made to target the host antigen CD81 and were shown to block Hepatitis C viral entry. The single-chain variable fragment of each antibody was crystallized in complex with the CD81 large extracellular loop (LEL) in order to guide affinity maturation of two distinct antibodies by phage display...
May 17, 2018: Journal of Molecular Biology
https://www.readbyqxmd.com/read/29778543/expression-of-a-functional-intrabody-against-hepatitis-c-virus-core-protein-in-escherichia-coli-and-silkworm-pupae
#4
Tatsuya Kato, Moeko Hasegawa, Takeshi Yamamoto, Takatsugu Miyazaki, Ryosuke Suzuki, Takaji Wakita, Tetsuro Suzuki, Enoch Y Park
It has been shown that the single-domain intrabody 2H9-L against the hepatitis C virus (HCV) capsid (core) protein inhibits the viral propagation and NF-κB promoter activity induced by the HCV core. In this study, 2H9-L fused with the FLAG tag sequence was expressed in both Escherichia coli and silkworm pupae and then purified. In addition, the full-length and its C terminal deletions of the HCV core protein, i.e., 1-123 amino acid residues (C123), 1-152 amino acid residues (C152), 1-177 amino acid residues (C177) and 1-191 amino acid residues (C191), were expressed as fusion proteins with a 6 × His tag at their N-terminus in E...
May 17, 2018: Protein Expression and Purification
https://www.readbyqxmd.com/read/29778513/the-immune-response-of-rhesus-macaques-to-novel-vaccines-comprising-hepatitis-b-virus-s-pres1-and-core-antigens
#5
Xia Chuai, Bangxiang Xie, Hong Chen, Xinyi Tan, Wen Wang, Baoying Huang, Yao Deng, Wenhui Li, Wenjie Tan
Therapeutic vaccines represent a unique approach to hepatitis B virus (HBV) treatment and have the potential to induce long-term control of infection. This study explored the immune responses of rhesus macaques to novel vaccines comprising the S, PreS1, and Core antigens of the HBV that showed promise as prophylactic and therapeutic approaches in a mouse model. The tested vaccines included two DNA vaccines (pVRC-SS1, pVRC-CS1), an HBV particle subunit (HBSS1) vaccine and the recombinant vaccinia virus- (RVJ-) based vaccines (RVJSS1 and RVJCS1) in which SS1 containing S (1-223 aa) and PreS1 (21-47 aa), CS1 containing Core (1-144 aa) and PreS1 (1-42 aa)...
May 16, 2018: Vaccine
https://www.readbyqxmd.com/read/29778267/the-road-to-hepatitis-c-virus-cure-practical-considerations-from-a-health-system-s-perspective
#6
REVIEW
M Cabell Jonas, Bernadette Loftus, Michael A Horberg
Hepatitis C virus infection remains a significant global health problem. Many individuals are unaware of their infection or disease stage. Innovations in care that promote rapid and easy identification of at-risk populations for screening, comprehensive diagnostic screening, and triage to curative direct-acting antiviral medications will accelerate efforts to eradicate hepatitis C.
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778266/estimation-of-hepatitis-c-disease-burden-and-budget-impact-of-treatment-using-health-economic-modeling
#7
REVIEW
Jagpreet Chhatwal, Qiushi Chen, Rakesh Aggarwal
Oral direct-acting antiviral agents have revolutionized treatment of hepatitis C virus (HCV) infection. Nonetheless, barriers exist to elimination of HCV as a public health threat including low uptake of treatment, limited budget allocations for HCV treatment, and low awareness rates of HCV status among infected people. Mathematical modeling provides a systematic framework to analyze and compare potential solutions and elimination strategies by simulating the HCV epidemic under different conditions. Such models evaluate impact of interventions in advance of implementation...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778265/a-guide-to-the-economics-of-hepatitis-c-virus-cure-in-2017
#8
REVIEW
Benjamin P Linas, Shayla Nolen
This commentary reviews the core principals of cost-effectiveness and applies them to the rapidly evolving context of hepatitis C virus treatment in the United States. The article provides a foundation of evidence that hepatitis C virus treatment provides good economic value, even though it is expensive, and even when treating people who inject drugs who are at high risk for hepatitis C virus reinfection. The price of medications has decreased, but the high price continues to limit access to care. This wedge between cost effectiveness and affordability stands front and center as one of the leading obstacles to elimination...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778264/hepatitis-c-virus-diagnosis-and-the-holy-grail
#9
REVIEW
Tanya L Applegate, Emmanuel Fajardo, Jilian A Sacks
The world has embraced the call for global elimination of hepatitis C virus by 2030. The unprecedented speed of therapeutic development and increased access to direct-acting antivirals has made elimination a possibility. We must screen hundreds of millions of people to diagnose and treat those currently infected. Global access to hepatitis C virus diagnostics will be a keystone to success. Key challenges must be overcome and systems optimized to ensure widespread access to existing diagnostics. Although promising technologies may soon transform the landscape, innovative strategies are needed to stimulate investment and accelerate the development of point-of-care hepatitis C virus diagnostics...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778263/hepatitis-c-virus-elimination-in-the-human-immunodeficiency-virus-coinfected-population-leveraging-the-existing-human-immunodeficiency-virus-infrastructure
#10
REVIEW
Meredith E Clement, Lauren F Collins, Julius M Wilder, Michael Mugavero, Taryn Barker, Susanna Naggie
The objective of this review is to consider how existing human immunodeficiency virus (HIV) infrastructure may be leveraged to inform and improve hepatitis C virus (HCV) treatment efforts in the HIV-HCV coinfected population. Current gaps in HCV care relevant to the care continuum are reviewed. Successes in HIV treatment are then applied to the HCV treatment model for coinfected patients. Finally, the authors give examples of HCV treatment strategies for coinfected patients in both domestic and international settings...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778262/understanding-and-addressing-hepatitis-c-virus-reinfection-among-men-who-have-sex-with-men
#11
REVIEW
Thomas C S Martin, Andri Rauch, Luisa Salazar-Vizcaya, Natasha K Martin
Hepatitis C virus reinfection rates among men who have sex with men are high. Factors associated with infection point to varied sexual and drug-related risks that could be targeted for interventions to prevent infection/reinfection. Modeling indicates that tackling increasing incidence and high reinfection rates requires high levels of hepatitis C virus treatment combined with behavioral interventions. Enhanced testing strategies and prompt retreating of reinfection may be required to promptly diagnosed reinfections...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778261/strategies-to-reduce-hepatitis-c-virus-reinfection-in-people-who-inject-drugs
#12
REVIEW
Marianne Martinello, Gregory J Dore, Gail V Matthews, Jason Grebely
Reinfection after direct-acting antiviral therapy may pose a challenge to hepatitis C virus elimination efforts. Reinfection risk is cited as a reason for not offering treatment to people who inject drugs. As treatment scale-up expands among populations with risks for reacquisition, acknowledgment that reinfection can and will occur is essential. Efforts to prevent and manage reinfection should be incorporated into individual- and population-level strategies. The risk of reinfection after successful treatment emphasises the need for education, harm reduction, and posttreatment surveillance...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778259/five-questions-concerning-managing-hepatitis-c-in-the-justice-system-finding-practical-solutions-for-hepatitis-c-virus-elimination
#13
REVIEW
Anne C Spaulding, Madeline G Adee, Robert T Lawrence, Jagpreet Chhatwal, William von Oehsen
An estimated 30% of Americans with hepatitis C virus (HCV) pass through a jail or prison annually. One in 7 incarcerated persons is viremic. Screening and treatment is cost-effective and beneficial to society as a whole. Yet at current (2018) levels of funding for HCV management, prisons are not aggressively seeking cases; few incarcerated persons with HCV actually receive treatment. This article explores barriers to screening for and treating hepatitis C in state prisons, and ways that states may overcome these barriers, such as nominal pricing...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778258/new-treatments-have-changed-the-game-hepatitis-c-treatment-in-primary-care
#14
REVIEW
Shelley N Facente, Katie Burk, Kelly Eagen, Elise S Mara, Aaron A Smith, Colleen S Lynch
In the pre-direct-acting antiviral era, hepatitis C virus (HCV) treatments were complex and largely managed by hepatologists, gastroenterologists, and infectious disease physicians. As direct-acting antivirals have driven up demand for treatment, the relative scarcity of these specialists has created a bottleneck effect, resulting in only a fraction of HCV-infected individuals offered treatment. The San Francisco Health Network is a safety net system of care. Its intervention was designed to be sustainable and scalable; with minimal time commitments for training providers, primary care-based HCV treatment increased 3-fold in a period of just over 3 years...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778257/localized-us-efforts-to-eliminate-hepatitis-c
#15
REVIEW
Annette Gaudino, Bryn Gay, Clifton Garmon, Mike Selick, Reed Vreeland, Katie Burk, Emalie Huriaux, Shelley N Facente, Annie Luetkemeyer, Phil Waters, Camilla S Graham
The United States has national plans for the elimination of hepatitis C virus but much of US health care is organized on the state level and requires local solutions. This article describes the plans developed by New York, Massachusetts, and the city/county of San Francisco for hepatitis C virus elimination. Coalitions capitalize on existing resources and advocate for new resources to address barriers in hepatitis C virus care. Although each coalition has distinct plans, all share a commitment to groups that are disproportionately affected and are at risk for being excluded from advances in hepatitis C virus treatment and cure...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778256/hepatitis-c-care-in-the-department-of-veterans-affairs-building-a-foundation-for-success
#16
REVIEW
Pamela S Belperio, Maggie Chartier, Rachel I Gonzalez, Angela M Park, David B Ross, Tim R Morgan, Lisa I Backus
The Department of Veterans Affairs (VA) has made significant progress in treating hepatitis C virus, experiencing more than a 75% reduction in veterans remaining to be treated since the availability of oral direct-acting antivirals. Hepatitis C Innovation Teams use lean process improvement and system redesign, resulting in practice models that address gaps in care. The key to success is creative improvements in veteran access to providers, including expanded use of nonphysician providers, video telehealth, and electronic technologies...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778255/elimination-of-hepatitis-c-virus-in-australia-laying-the-foundation
#17
REVIEW
Gregory J Dore, Behzad Hajarizadeh
Australia is on-track to achieve World Health Organization hepatitis C virus (HCV) elimination targets. An active HCV screening program led to 82% of HCV-infected population being diagnosed. An unrestricted direct-acting antiviral (DAA) program, launched in March 2016 resulted in an estimated 58,500 individuals (26% of total HCV-infected population, including 70% of those with cirrhosis) initiating treatment through 2017. Treatment uptake was high among sub-populations at greater HCV transmission risk with 22% of people injecting drugs and >60% of those with HIV/HCV coinfection initiating DAA treatment in 2016...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778254/long-term-liver-disease-treatment-and-mortality-outcomes-among-17-000-persons-diagnosed-with-chronic-hepatitis-c-virus-infection-current-chronic-hepatitis-cohort-study-status-and-review-of-findings
#18
REVIEW
Anne C Moorman, Loralee B Rupp, Stuart C Gordon, Yuna Zhong, Jian Xing, Mei Lu, Joseph A Boscarino, Mark A Schmidt, Yihe G Daida, Eyasu H Teshale, Philip R Spradling, Scott D Holmberg
Chronic Hepatitis Cohort Study (CHeCS) publications using data from "real-world" patients with hepatitis C virus (HCV) have described demographic disparities in access to care; rates of advanced liver disease, morbidity, and mortality (2.5%-3.5% per year during 2006-10, although only 19% of all CHeCS decedents, and just 30% of those with deaths attributed to liver disease, had HCV listed on death certificate); substantial comorbidities, such as diabetes, advanced liver fibrosis (29% prevalence), renal disease, and depression, and partial reversal of all these with successful antiviral therapy; patient risk behaviors; and use of noninvasive markers to assess liver disease...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29777749/burden-of-liver-disease-in-europe-epidemiology-and-analysis-of-risk-factors-to-identify-prevention-policies
#19
REVIEW
Laura Pimpin, Helena Cortez-Pinto, Francesco Negro, Emily Corbould, Jeffrey V Lazarus, Laura Webber, Nick Sheron
BACKGROUND & AIMS: The burden of liver disease in Europe continues to grow. We aimed to describe the epidemiology of liver diseases and their risk factors in European countries, and identify public health interventions that could impact on these risk factors to reduce the burden of liver disease. METHODS: As part of the HEPAHEALTH project, commissioned by EASL, we extracted information on historical and current prevalence and mortality from national and international literature and databases on liver disease in 35 countries in the WHO European region, as well as historical and recent prevalence data on their main determinants; alcohol consumption, obesity and hepatitis B and C virus infections...
May 16, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29777191/eradication-of-hepatitis-c-virus-is-associated-with-the-attenuation-of-steatosis-as-evaluated-using-a-controlled-attenuation-parameter
#20
Kohei Shimizu, Yoko Soroida, Masaya Sato, Hiromi Hikita, Tamaki Kobayashi, Momoe Endo, Mamiko Sato, Hiroaki Gotoh, Tomomi Iwai, Ryosuke Tateishi, Kazuhiko Koike, Yutaka Yatomi, Hitoshi Ikeda
Chronic hepatitis C virus (HCV) infection was shown to cause hepatic steatosis or suppression of serum lipid levels. However, little is known about the changes in hepatic steatosis following HCV eradication. We aimed to evaluate this issue using the controlled attenuation parameter (CAP), which was recently shown to provide a standardized non-invasive measure of hepatic steatosis. We enrolled 70 patients with chronic HCV infections and steatosis (CAP of over 248 dB/m) who had achieved a sustained viral response at 12 weeks after discontinuation of antiviral treatment using direct-acting antivirals (DAA)...
May 18, 2018: Scientific Reports
keyword
keyword
18361
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"